Berry Genomics Co Ltd (000710) - Total Liabilities
Based on the latest financial reports, Berry Genomics Co Ltd (000710) has total liabilities worth CN¥694.43 Million CNY (≈ $101.62 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 000710 net asset momentum to track the company's year-over-year net asset growth rate.
Berry Genomics Co Ltd - Total Liabilities Trend (1994–2024)
This chart illustrates how Berry Genomics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 000710 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Berry Genomics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Berry Genomics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
|
China | CN¥987.73 Million |
|
Genesco Inc
NYSE:GCO
|
USA | $831.59 Million |
|
Medistim ASA
OL:MEDI
|
Norway | Nkr151.23 Million |
|
Prince Housing & Development Corp
TW:2511
|
Taiwan | NT$21.20 Billion |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
F:GU5
|
Germany | €47.87 Billion |
|
Nouveau Monde Graphite Inc
NYSE:NMG
|
USA | $94.52 Million |
|
Trade-Van Information Services Co
TW:6183
|
Taiwan | NT$1.78 Billion |
|
Heidelberger Druckmaschinen Aktiengesellschaft
F:HDD
|
Germany | €1.59 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down Berry Genomics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Berry Genomics Co Ltd (000710) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Berry Genomics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Berry Genomics Co Ltd (1994–2024)
The table below shows the annual total liabilities of Berry Genomics Co Ltd from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥669.56 Million ≈ $97.98 Million |
-20.91% |
| 2023-12-31 | CN¥846.56 Million ≈ $123.88 Million |
-2.87% |
| 2022-12-31 | CN¥871.54 Million ≈ $127.53 Million |
-12.50% |
| 2021-12-31 | CN¥996.02 Million ≈ $145.75 Million |
+21.24% |
| 2020-12-31 | CN¥821.52 Million ≈ $120.21 Million |
+13.81% |
| 2019-12-31 | CN¥721.83 Million ≈ $105.63 Million |
+206.28% |
| 2018-12-31 | CN¥235.68 Million ≈ $34.49 Million |
-4.17% |
| 2017-12-31 | CN¥245.94 Million ≈ $35.99 Million |
-43.33% |
| 2016-12-31 | CN¥433.97 Million ≈ $63.50 Million |
+13.84% |
| 2015-12-31 | CN¥381.19 Million ≈ $55.78 Million |
+20.70% |
| 2014-12-31 | CN¥315.83 Million ≈ $46.22 Million |
+9.25% |
| 2013-12-31 | CN¥289.09 Million ≈ $42.30 Million |
+33.01% |
| 2012-12-31 | CN¥217.34 Million ≈ $31.80 Million |
-6.61% |
| 2011-12-31 | CN¥232.73 Million ≈ $34.06 Million |
-10.85% |
| 2010-12-31 | CN¥261.04 Million ≈ $38.20 Million |
+3.78% |
| 2009-12-31 | CN¥251.54 Million ≈ $36.81 Million |
+21.55% |
| 2008-12-31 | CN¥206.93 Million ≈ $30.28 Million |
+57.32% |
| 2007-12-31 | CN¥131.54 Million ≈ $19.25 Million |
-9.20% |
| 2006-12-31 | CN¥144.87 Million ≈ $21.20 Million |
+7.10% |
| 2005-12-31 | CN¥135.26 Million ≈ $19.79 Million |
-18.41% |
| 2004-12-31 | CN¥165.77 Million ≈ $24.26 Million |
+13.31% |
| 2003-12-31 | CN¥146.30 Million ≈ $21.41 Million |
+9.82% |
| 2002-12-31 | CN¥133.22 Million ≈ $19.49 Million |
-31.96% |
| 2001-12-31 | CN¥195.81 Million ≈ $28.65 Million |
+56.24% |
| 2000-12-31 | CN¥125.33 Million ≈ $18.34 Million |
+61.14% |
| 1999-12-31 | CN¥77.77 Million ≈ $11.38 Million |
-19.27% |
| 1998-12-31 | CN¥96.34 Million ≈ $14.10 Million |
-7.65% |
| 1997-12-31 | CN¥104.33 Million ≈ $15.27 Million |
-16.64% |
| 1996-12-31 | CN¥125.15 Million ≈ $18.31 Million |
+31.18% |
| 1995-12-31 | CN¥95.40 Million ≈ $13.96 Million |
+55.54% |
| 1994-12-31 | CN¥61.33 Million ≈ $8.98 Million |
-- |
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more